Meeting
2022 ASCO Annual Meeting
Analysis of the contribution of macrophages to the overall tumor PD-L1 microenvironment using a screening multi-tumor tissue microarray and rapid multiplex fluorescence digital phenotyping approach.
Authors
Marie Cumberbatch
TriStar Technology Group LLC, Washington, DC
Marie Cumberbatch , Douglas Wood , Gourab Chatterjee , Christopher Womack , Milan Bhagat , Lorcan Sherry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2620)
DOI
10.1200/JCO.2022.40.16_suppl.2620
Abstract #
2620
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Alterations in tumor immune microenvironment and progressive immune exhaustion with advancing penile squamous cell carcinoma using multiplex immunofluorescence and image analysis.
First Author: Keerthi Gullapalli
Poster
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
First Author: Weihua Guo
Poster
2016 ASCO Annual Meeting
Tumor-infiltrating CD204+ M2 macrophages compared to T cells as a prognosticator for patients with uterine cervical adenocarcinoma.
First Author: Asuka Kawachi
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero